Cowen Increases Teladoc Health (NYSE:TDOC) Price Target to $100.00

Teladoc Health (NYSE:TDOC) had its price objective raised by Cowen from $86.00 to $100.00 in a research note issued to investors on Monday morning, The Fly reports. They currently have an outperform rating on the health services provider’s stock.

Several other equities analysts have also commented on the company. SunTrust Banks reissued a hold rating and set a $80.00 price target on shares of Teladoc Health in a research report on Monday, December 2nd. UBS Group assumed coverage on Teladoc Health in a research report on Friday, January 10th. They set a neutral rating and a $90.00 price target on the stock. Wells Fargo & Co boosted their price target on Teladoc Health from $77.00 to $95.00 and gave the stock an overweight rating in a research report on Wednesday, January 8th. Stifel Nicolaus assumed coverage on Teladoc Health in a research report on Monday, November 25th. They set a hold rating and a $83.00 price target on the stock. Finally, Jefferies Financial Group lowered Teladoc Health from a buy rating to a hold rating and set a $80.00 price target on the stock. in a research report on Friday, December 6th. Nine equities research analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the company. The stock currently has a consensus rating of Buy and a consensus price target of $87.71.

Teladoc Health stock opened at $94.00 on Monday. The stock’s 50 day moving average price is $82.71 and its 200 day moving average price is $72.24. The firm has a market capitalization of $6.80 billion, a PE ratio of -65.28 and a beta of 1.38. The company has a debt-to-equity ratio of 0.44, a quick ratio of 6.55 and a current ratio of 6.55. Teladoc Health has a one year low of $48.57 and a one year high of $98.97.

Teladoc Health (NYSE:TDOC) last released its quarterly earnings results on Wednesday, October 30th. The health services provider reported ($0.28) EPS for the quarter, topping the consensus estimate of ($0.40) by $0.12. The firm had revenue of $137.96 million for the quarter, compared to analyst estimates of $136.46 million. Teladoc Health had a negative return on equity of 11.23% and a negative net margin of 20.15%. Teladoc Health’s revenue for the quarter was up 24.3% on a year-over-year basis. During the same period in the previous year, the company posted ($0.34) EPS. On average, analysts forecast that Teladoc Health will post -1.55 earnings per share for the current fiscal year.

In other news, insider Lewis Levy sold 2,025 shares of the business’s stock in a transaction that occurred on Monday, December 2nd. The stock was sold at an average price of $80.50, for a total value of $163,012.50. Following the completion of the sale, the insider now directly owns 5,655 shares in the company, valued at approximately $455,227.50. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, CAO Gabriel R. Cappucci sold 9,569 shares of the business’s stock in a transaction that occurred on Thursday, October 31st. The shares were sold at an average price of $75.00, for a total value of $717,675.00. Following the completion of the sale, the chief accounting officer now owns 10,798 shares of the company’s stock, valued at $809,850. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 68,099 shares of company stock worth $5,151,311. 3.14% of the stock is currently owned by corporate insiders.

Several hedge funds and other institutional investors have recently modified their holdings of TDOC. Nuveen Asset Management LLC increased its holdings in shares of Teladoc Health by 2,939.6% in the 2nd quarter. Nuveen Asset Management LLC now owns 608,824 shares of the health services provider’s stock valued at $40,432,000 after acquiring an additional 588,794 shares during the last quarter. Waddell & Reed Financial Inc. increased its holdings in shares of Teladoc Health by 32.5% in the 2nd quarter. Waddell & Reed Financial Inc. now owns 2,335,837 shares of the health services provider’s stock valued at $155,123,000 after acquiring an additional 572,388 shares during the last quarter. Macquarie Group Ltd. increased its holdings in shares of Teladoc Health by 59.9% in the 2nd quarter. Macquarie Group Ltd. now owns 1,490,807 shares of the health services provider’s stock valued at $99,005,000 after acquiring an additional 558,650 shares during the last quarter. Sumitomo Mitsui Trust Holdings Inc. increased its holdings in shares of Teladoc Health by 114.7% in the 3rd quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 1,041,327 shares of the health services provider’s stock valued at $70,519,000 after acquiring an additional 556,269 shares during the last quarter. Finally, Nikko Asset Management Americas Inc. increased its holdings in shares of Teladoc Health by 44.3% in the 3rd quarter. Nikko Asset Management Americas Inc. now owns 1,041,327 shares of the health services provider’s stock valued at $70,519,000 after acquiring an additional 319,556 shares during the last quarter.

Teladoc Health Company Profile

Teladoc Health, Inc provides telehealth services. It offers a portfolio of services and solutions covering 450 medical subspecialties, such as flu and upper respiratory infections, cancer, and congestive heart failure. The company provides its services through mobile devices, the Internet, video, and phone.

Featured Story: If I purchase shares through a brokerage account, am I the holder of record?

The Fly

Analyst Recommendations for Teladoc Health (NYSE:TDOC)

Receive News & Ratings for Teladoc Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teladoc Health and related companies with MarketBeat.com's FREE daily email newsletter.